Xilio Therapeutics Inc
xiliotx.comWhat Do They Do?
Develops masked cancer immunotherapies designed to activate in tumors, including antibody-based therapies and T cell engagers, for people with cancer.
10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of…View ↗
Leveraging our proprietary, clinically-validated masking technology, we are advancing two wholly-owned programs for masked T cell engagers…View ↗
In addition, in February 2025, our wholly owned subsidiary, Xilio Development, Inc., or Xilio Development, entered into a collaboration…View ↗
How Do They Make Money?
Pharmaceutical partners pay for licenses to drug programs and related development work through upfront fees and milestone payments; agreements can also include research-cost reimbursements and royalties on licensed-product sales. Payments follow each contract’s billing schedule.
10-K for FY2025, filed Mar 23, 2026
$43.8M
-
10-K for FY2025, filed Mar 23, 2026
$43.8M ↗
Who Are Their Customers?
Xilio works with pharmaceutical partners such as AbbVie and Gilead through license and collaboration agreements covering drug rights and development work.
10-K for FY2025, filed Mar 23, 2026In addition, in February 2025, our wholly owned subsidiary, Xilio Development, Inc., or Xilio Development, entered into a collaboration…View ↗
In March 2024, our wholly owned subsidiary Xilio Development entered into an exclusive license agreement with Gilead related to…View ↗
The Company determined that the Collaboration Agreement represents a contract with a customer within the scope of ASC 606 and identified…View ↗
The Company determined that the License Agreement represents a contract with a customer within the scope of ASC 606 and identified two…View ↗
Do Revenues Turn Into Profits?
No. It lost $35M in FY2025.
10-K for FY2025, filed Mar 23, 2026
−$42MView ↗
10-K for FY2025, filed Mar 23, 2026
−$35MView ↗
10-K for FY2025, filed Mar 23, 2026
−$5.5MView ↗
How Are They Changing?
Masked T cell engagers
The older report described candidates built around cytokines and checkpoint inhibitors; the latest also describes masked T cell engagers aimed at tumor-associated antigens.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology, or I-O, therapies with the goal…View ↗
Leveraging our proprietary, clinically-validated masking technology, we are advancing two wholly-owned programs for masked T cell engagers…View ↗
PSMA+STEAP1 with co-stimulation (SEECR format): We are advancing a multi-specific masked T cell engager program targeting PSMA and STEAP1…View ↗
CLDN18.2 (ATACR format): We are advancing a masked T cell engager program targeting CLDN18.2 (ATACR format). Our modular design…View ↗
Partnered programs
The older report described Xilio as retaining development and commercialization rights; the latest describes collaboration and licensing arrangements for its programs.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 23, 2026We currently have worldwide development and commercialization rights to all of our product candidates.View ↗
Loading...
